Are we sure personal genomics is a good business?
One year ago, Nebula Genomics was “pleased to offer free whole genome sequencing” to anyone willing to complete some surveys. Yesterday, it was pleased to pivot, now offering whole genome sequencing for $299 plus a subscription fee.
As OneZero reports, Nebula’s new business model still amounts to the cheapest way to get your genome sequenced, but it remains unclear whether that’s a product consumers particularly want. Veritas Genetics slashed the price of its sequencing service from $999 to $599, and then it shut down U.S. operations within six months.
Meanwhile, 23andMe and Ancestry, companies that sell much less exhaustive genetic tests, have laid off employees amid a dip in demand for at-home tests. Illumina, the biggest maker of testing machines, has forecast declining sales for the products it sells consumer genetics companies.
Nebula is betting that offering more genetic information and emphasizing privacy will make its offering successful. But the lesson from the company’s rivals might be that personal genomics is a shrinking market.
As OneZero reports, Nebula’s new business model still amounts to the cheapest way to get your genome sequenced, but it remains unclear whether that’s a product consumers particularly want. Veritas Genetics slashed the price of its sequencing service from $999 to $599, and then it shut down U.S. operations within six months.
Meanwhile, 23andMe and Ancestry, companies that sell much less exhaustive genetic tests, have laid off employees amid a dip in demand for at-home tests. Illumina, the biggest maker of testing machines, has forecast declining sales for the products it sells consumer genetics companies.
Nebula is betting that offering more genetic information and emphasizing privacy will make its offering successful. But the lesson from the company’s rivals might be that personal genomics is a shrinking market.
.png)
No hay comentarios:
Publicar un comentario